BHVN
Price:
$35.625
Market Cap:
$3.60B
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amy...[Read more]
Industry
Biotechnology
IPO Date
2022-09-23
Stock Exchange
NYSE
Ticker
BHVN
According to Biohaven Pharmaceutical Holding Company Ltd.’s latest financial reports and current stock price. The company's current ROE is -225.12%. This represents a change of 295.94% compared to the average of -56.86% of the last 4 quarters.
The mean historical ROE of Biohaven Pharmaceutical Holding Company Ltd. over the last ten years is 799.75%. The current -225.12% ROE has changed -128.15% with respect to the historical average. Over the past ten years (40 quarters), BHVN's ROE was at its highest in in the December 2019 quarter at 2.01%. The ROE was at its lowest in in the March 2021 quarter at -345.10%.
Average
799.75%
Median
-95.37%
Minimum
-707.16%
Maximum
7.12%
Discovering the peaks and valleys of Biohaven Pharmaceutical Holding Company Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 7.12%
Minimum Annual Increase = 0%
Minimum Annual ROE = -707.16%
Year | ROE | Change |
---|---|---|
2023 | -95.37% | -9.90% |
2022 | -105.85% | -82.82% |
2021 | -616.29% | -12.85% |
2020 | -707.16% | -109.93% |
2019 | 7.12% | Infinity% |
2018 | 0% | 0% |
The current ROE of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-272.50%
5-year avg
1.12%
10-year avg
799.75%
Biohaven Pharmaceutical Holding Company Ltd.’s ROE is greater than Immunome, Inc. (-139.72%), less than Inhibrx Biosciences, Inc. (1.45%), less than AgeX Therapeutics, Inc. (172.71%), greater than Icosavax, Inc. (-20.22%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Mereo BioPharma Group plc (-69.11%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Blueprint Medicines Corporation (-47.66%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Revolution Medicines, Inc. (-33.67%), greater than C4 Therapeutics, Inc. (-42.45%), less than Agios Pharmaceuticals, Inc. (70.20%), greater than Nurix Therapeutics, Inc. (-63.39%),
Company | ROE | Market cap |
---|---|---|
-139.72% | $696.88M | |
1.45% | $210.05M | |
172.71% | $27.76M | |
-20.22% | $769.04M | |
-22.40% | $1.29B | |
-32.76% | $489.67M | |
-32.51% | $127.23M | |
-88.42% | $189.19M | |
-69.11% | $573.29M | |
-103.92% | $4.11B | |
-47.66% | $5.77B | |
-98.94% | $8.19B | |
-40.45% | $4.12B | |
-85.39% | $277.62M | |
-24.96% | $2.65B | |
-33.67% | $8.16B | |
-42.45% | $277.20M | |
70.20% | $1.95B | |
-63.39% | $1.39B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biohaven Pharmaceutical Holding Company Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biohaven Pharmaceutical Holding Company Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Biohaven Pharmaceutical Holding Company Ltd.'s ROE?
How is the ROE calculated for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
What is the highest ROE for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
What is the 3-year average ROE for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
What is the 5-year average ROE for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
How does the current ROE for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) compare to its historical average?